At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Natural Human Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu in Perth, Western Australia
In Brief
A Phase 2 clinical trial evaluating interferon-alpha and placebo for Upper Respiratory Tract Infections. Completed, enrolled 200 participants across 1 site.
Detailed Summary
The aim of the study is to see if lozenges containing a low dose of interferon-alpha can prevent and/or reduce the severity of colds and flu. Starting about 1 month before the expected start of the winter colds and flu season in Perth, Australia, healthy volunteers will allow a lozenge containing interferon, or a lozenge containing no medicine (a placebo), to dissolve in their mouth once a day for 16 weeks. Blood tests at the start and end of treatment will determine whether interferon was able to prevent infections with cold/flu viruses. Once a week, volunteers will complete a survey about their cold/flu symptoms, medications taken, days of work missed, etc. to see if interferon was able to make their winter colds and flu less severe.
Study Details
Timeline
Interventions
a lozenge for oral dissolution containing 150 international units of human interferon-alpha taken once daily for 16 weeks
placebo lozenges for oral dissolution taken once daily for 16 weeks